Affimed N.V. Completes Enrollment in NSCLC Cohort and Prepares for Data Presentations at ASH 2024
Affimed N.V. reports on clinical trials, financial results, and updates on cash position through Q4 2025.Quiver AI SummaryAffimed N.V. announced the completion of enrollment in the EGFR wild-type non-small...
Why Shares of Affimed Fell Thursday
The clinical-stage biotech focuses on immuno-oncology therapies.
Why Affimed Stock Plummeted by Over 16% Today
An analyst's downgrade brings out the bears for the European cancer treatment developer.